From: The role of tumor necrosis factor-alpha in systemic lupus erythematosus
 |  | New ANA | New anti-dsDNA | New ACLA |  |  | |||
---|---|---|---|---|---|---|---|---|---|
Diagnosis | Number | Positive | Positivea | IgM | IgG | IgM | IgG | DIL | Reference |
RA | 156 | 37 (24%) | 22 (14%) | 22 | 1 | ND | ND | 1 | [20] |
RA | 62 | 19 (31%) | 7 (11%) | 7 | 0 | ND | ND | 0 | [22] |
RA | 24 | 4 (17%) | 13 (54%) | 9–11 | 3–4 | 5 | 0 | 0 | [24] |
RA | 59 | 24 (41%) | 21 (36%) | 19 | 2 | ND | ND | 0 | [26] |
RA | 53 | 29 (55%) | 5 (9%) | 22b | 34b | 0 | 0 | 2 | [27] |
RA | 59 | 24 (41%) | 29 (49%) | 28 | 1 | 0 | 0 | 0 | [28] |
RA | 57 | 28 (49%) | Â | ND | 3 | ND | ND | 1 | [31] |
All RA | 413 | 165 (40%) | 77 (19%) | Â | Â | Â | Â | 4 (1.0%) | Â |
AS | 15 | 9 (60%) | 4 (27%) | 4 | 0–1 | 1 | 3 | 0 | [24] |
SpA | 21 | 12 (57%) | 4 (19%) | ND | ND | ND | ND | 0 | [21] |
SpA | 35 | 25 (71%) | 6 (17%) | 6 | 0 | ND | ND | 0 | [22] |
SpA | 33 | 8 (24%) | 11 (33%) | 11 | 0 | ND | ND | 0 | [29] |
All SpA | 94 | 54 (57%) | 25 (27%) | Â | Â | Â | Â | 0 (0%) | Â |
CD | 35 | 6 (17%) | 3 (9%) | ND | ND | ND | ND | 0 | [23] |
CD | 125 | 71 (57%) | 14 (11%) | ND | ND | ND | ND | 2 | [25] |
CD | 500 | ND | ND | ND | ND | ND | ND | 3 | [35] |
CD | 63 | 21 (33%) | 9 (14%) | ND | 9 | 2 | 0 | 1 | [30] |
All CD | 723 | Â | Â | Â | Â | Â | Â | 6 (0.8%) | Â |
All together | 1,230 | Â | Â | Â | Â | Â | Â | 10 (0.8%) | Â |